Table 2 Comparison of the final participant group with all other non-participants.
From: Recruitment of representative samples for low incidence cancer populations: Do registries deliver?
| Â | Demographics of survivors | |||||||
|---|---|---|---|---|---|---|---|---|
| Â | Stage 1 (n = 468) | Stage 2 (n = 232) | Stage 3 (n = 64) | Total (n = 468) | ||||
| Â | Clinician did not consent (n = 102) | Unable to contact clinician (n = 134) | Survivor did not consent (n = 18) | Unable to contact survivor (n = 150) | Survivor did not consent (n = 20) | Unable to contact survivor (n = 12) | Did not consent and unable to contact (n = 436) | Final participant group (n = 32) |
| Â | n (%) | n (%) | n (%) | n (%) | n (%) | n (%) | n (%) | n (%) |
Age at diagnosis | Â | Â | Â | Â | Â | Â | Â | |
14-15 | 27 (26) | 30 (22) | 9 (50) | 40 (27) | 2 (10) | 2 (17) | 110 (25)* | 11 (34) |
16-17 | 27 (26) | 51 (38) | 2 (11) | 46 (31) | 8 (40) | 6 (50) | 140 (32) | 16 (50) |
18-19 | 48 (47) | 53 (40) | 7 (39) | 64 (43) | 10 (50) | 4 (33) | 186 (43)* | 5 (16) |
Gender | Â | Â | Â | Â | Â | Â | Â | Â |
Female | 44 (43) | 59 (44) | 7 (39) | 68 (45) | 4 (20) | 8 (67) | 190 (44) | 17 (53) |
Male | 58 (57) | 75 (56) | 11 (61) | 82 (55) | 16(80) | 4 (33) | 246 (56) | 15 (47) |
Cancer type | Â | Â | Â | Â | Â | Â | Â | |
Lymphoma | 16 (16) | 36 (27) | 5 (28) | 36 (24) | 4 (20) | 2 (17) | 99 (23) | 6 (19) |
Skin | 25 (25) | 21 (16) | 3 (17) | 31 (21) | 2 (10) | 2 (17) | 84 (19) | 2 (6.2) |
Testicular | 9 (8.8) | 13 (9.7) | 0 (0) | 13 (8.6) | 4 (20) | 0 (0) | 39 (8.9) | 1 (3.1) |
Thyroid | 11 (11) | 7 (5.2) | 0 (0) | 11 (7.3) | 2 (10) | 1 (8.3) | 32 (7.3) | 3 (9.3) |
Leukaemia | 13 (13) | 17 (13) | 3 (17) | 21 (14) | 2 (10) | 2 (17) | 58 (13) | 8 (25) |
Other** | 28 (27) | 40 (30) | 7 (39) | 38 (25) | 6 (30) | 5 (42) | 124 (28) | 12 (38) |